J. B. Chemicals & Pharmaceuticals

Company Description

J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. It specializes in gastroenterology, hypertension, dermatology, nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT), manufacturing pharmaceutical formulations, herbal remedies, and APIs. Brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. The company has a direct presence in Russia and South Africa, with distributor relationships in the United States, Asia, Africa, and Latin America. In the last fiscal year, the company had a market cap of $3005 millions, profits of $292 millions, revenue of $459 millions, and 5517 employees.

Analysis

ANALYSIS: With an Obermatt 360° View of 81 (better than 81% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock J. B. Chemicals & Pharmaceuticals are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for J. B. Chemicals & Pharmaceuticals. The consolidated Growth Rank has a good rank of 73, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 73% of competitors in the same industry. The consolidated Safety Rank at 73 means that the company has a financing structure that is safer than 73% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 92, which means that professional investors are more optimistic about the stock than for 92% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 37, meaning that the share price of J. B. Chemicals & Pharmaceuticals is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 63% of alternative stocks in the same industry. ...read more

Country

India

Industry Pharmaceuticals

Size Small

Website jbcpl.com

Index

Add to Watchlist

See Similar Stocks

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.